News
Twitter
Videos
Images
Events
News For Gilead Sciences
This RSS feed URL is deprecated
This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news
Google
9/25/2018 8:34:39 PM
Gilead to launch generic versions of its hepatitis drugs - Reuters
Reuters
Gilead
to launch generic versions of its hepatitis drugs
Reuters
Gilead
said the low-cost variants of the drugs will be available at a list price of $24,000 for the most common course of therapy from January. U.S. healthcare companies, ranging from insurers to drug retailers, are stepping up efforts to combat rising
...
Gilead
to Sell Cheaper Versions of Drug That Sparked Cost Debate
Bloomberg
Gilead to Slice List Prices of Liver Drugs - WSJ
Wall Street Journal
Gilead
to offer cheaper version of its $1000 a pill hepatitis drugs
Business Insider
Pharmacy Times
-
StreetInsider.com
-
Express Scripts
all 61 news articles »
Google
9/24/2018 8:51:00 PM
Brazil court strips Gilead of hepatitis C drug patent | Reuters - Reuters
Reuters
Brazil court strips Gilead of hepatitis C drug patent | Reuters
Reuters
BRASILIA/SAO PAULO (Reuters) - A Brazilian court has stripped the patent protection of a Gilead Sciences Inc big-selling hepatitis C treatment in Brazil at the ...
Brazil court strips
Gilead
of hepatitis C drug patent
WHBL News
Brazil court strips
Gilead
hepatitis drug patent, politician says
Fiji Times
all 28 news articles »
Google
9/24/2018 8:27:30 PM
Gilead to launch generic versions of Epclusa and Harvoni - Seeking Alpha
Gilead
to launch generic versions of Epclusa and Harvoni
Seeking Alpha
Gilead Sciences
(NASDAQ:GILD) announces that newly created subsidiary Asegua Therapeutics LLC will launch authorized generic versions of hepatitis C meds Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir) in the U.S.. The drugs ...
Google
9/24/2018 12:42:00 PM
What's Next For Gilead? - Seeking Alpha
What's Next For
Gilead
?
Seeking Alpha
Gilead
(GILD) reported better than expected Q2 results and has been making progress with its pipeline over the last couple of months. It looks like 2018 could be the bottom, and revenues might increase again next year. This, coupled with a promising
...
Google
9/21/2018 12:33:47 PM
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Yahoo Finance
Gilead Sciences
(GILD) Outpaces Stock Market Gains: What You Should Know
Yahoo Finance
Gilead Sciences
(GILD) closed at $73.88 in the latest trading session, marking a +0.31% move from the prior day. This move outpaced the S&P 500's daily gain of 0.13%. At the same time, the Dow added 0.61%, and the tech-heavy Nasdaq lost 0.08%.
and more »
Google
9/19/2018 9:45:00 PM
Gilead Faces Doubts on Wall Street a Year After $12 Billion Deal - Bloomberg
Bloomberg
Gilead
Faces Doubts on Wall Street a Year After $12 Billion Deal
Bloomberg
Sales of Kite's first treatment, Yescarta, failed to impress in its first two full quarters on the market and competition is looming. Adding to concerns,
Gilead's
long-time chairman, chief executive officer and chief medical officer have all recently
...
and more »
Google
9/19/2018 6:36:59 PM
Gilead: Forming A Base? - Seeking Alpha
Zacks.com
Gilead
: Forming A Base?
Seeking Alpha
Biotech stocks have surged this year, soundly outperforming the S&P 500.
Gilead Sciences
should benefit from these trends and may be forming a base in its latest moves higher. Sequential revenue gains and rising EPS guidance factors suggest Gilead's ...
Is
Gilead
(GILD) a Suitable Stock for Value Investors Now?
Zacks.com
There's Some Concern Under The Hood:
Gilead Sciences
, Inc. (GILD)
NMSU Nеws
Notable Intraday Movers:
Gilead Sciences
, Inc., (NASDAQ: GILD), ServiceNow, Inc., (NYSE: NOW)
Global Export Lines (press release)
Fairfield Current
-
Nyse Trading News (press release)
-
StockNewsGazette
-
Zacks
all 201 news articles »
Google
9/18/2018 1:35:00 PM
1
2